Condition: Advanced Solid Tumors With MTAP Gene Deletion · Sponsor: Suzhou Genhouse Bio Co., Ltd.
This is a multicenter, single-arm, open-label, dose-escalation, dose-expansion study to evaluate the safety, tolerability, PK/PD, and preliminary anti-tumor activity of GH56 Capsule in subjects with advanced solid tumors who have failed or are intolerant in standard treatment, or have no standard therapy. The clinical trial will be carried out in two parts: phase Ia study (dose escalation study) and phase Ib (dose expansion study).
This description comes directly from the study's public registry record.
Yiming Zhou, Bachelor · +86-0512-86861608 · zhouyiming@genhousebio.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Shanghai Sixth People's Hospital | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Shanghai GoBroad Caner Hospital China Pharmaceutical University | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Shanxi Provincial Cancer Hospital | Taiyuan, Shanxi, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06796699